Stock Detail
SUPERGEN INC
Drug Manufacturers Other
SUPG @ Yahoo Finance | SUPG Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.79 | $1.84 | $-0.01 | -0.56% | 0.00 | $1.80 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.78 | $1.78 | 149,926 | 166.26M | 343,250 | 9.70 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.86 | 1.82 | 1.80 | 1.76 | 1.74 |
Stock Profile
SuperGen, Inc., a pharmaceutical company, engages in the development and commercialization of the therapies for solid tumors, hematological malignancies, and blood disorders. The company offers Orathecin capsules, a second-generation topoisomerase I inhibitor, which causes single-strand breaks in the DNA of rapidly dividing tumor cells; Dacogen, a pyrimidine analog that decreases the amount of methylation at certain DNA sites; and Nipentis that is used for the treatment of hairy cell leukemia, a type of B-lymphocytic leukemia, as well as shows activity in various autoimmune diseases, including GvHD, bone marrow transplantation and multiple sclerosis. It also offers Mitomycin, Paclitaxel, Mitozytrex, Inhaled Orathecin, Partaject Orathecin, CZ 112, and Cremophor-free paclitaxel for solid tumors; Daunorubicin for Acute leukemias; Surface Safe for surface decontaminate; Partaject busulfan for Neoplastic meningitis/bone marrow transplant; Avicine for Therapeutic Vaccine; and VEGF for anti-angiogenesis. The company sells its products to cancer hospitals, clinics, private practice oncology clinics, oncology distributors, and drug wholesalers in the United States. SuperGen was founded in 1991 and is headquartered in Dublin, California.